Johnson & Johnson Focuses on Cardiovascular Growth Amid MedTech Expansion
Johnson & Johnson is targeting high-end growth in the MedTech sector, with a focus on cardiovascular products. The company expects to achieve operational market growth at the upper end of its 5%–7% target through 2027, driven by acquisitions like Abiomed and Shockwave as well as advancements in electrophysiology (EP). Tim Schmid, MedTech Chairman, emphasized a shift toward decentralized business units for faster decision-making. The company also plans to separate its orthopedics division around mid-2027 but has not yet decided on the structure of this separation. Despite international competition and challenges in China's procurement landscape, Johnson & Johnson remains confident in its cardiovascular strategy. It is developing new technologies such as pulsed-field ablation catheters and the OTTAVA surgical robot to maintain a competitive edge. Schmid noted that while EP adoption has been slower outside of the U.S., particularly due to regulatory delays for PFA technology, J&J continues to invest heavily in its Biosense Webster franchise. The company is also preparing for potential impacts from China's volume-based procurement program on the EP market later this year or into 2027. Despite these challenges, Johnson & Johnson remains optimistic about long-term growth and innovation within MedTech.
Tickers: $JNJ
Topics: Cardiovascular Products Growth Outlook MedTech Orthopedics Separation